Switch theme
Sign up to access all valuation multiples
Cosmecca Korea Co Ltd is engaged in research, development, and production of cosmetics. It offers various products including skincare, makeup products, and functional products. The skincare products consist of Cream, Essence, Cleansers, Korean herbal products, Exfoliators, and mask sheets. Its functional products comprise of skincare products with specific functions such as UV blocking, brightening, and wrinkle care. The Makeup products range comprise of BB & CC cream, Skin cover balms, Makeup base, Foundation, Concealer, Lipstick, Mascara, and Powders.
1999
n/a
LTM Revenue $396M
LTM EBITDA $59.4M
$446M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cosmecca Korea has a last 12-month revenue (LTM) of $396M and a last 12-month EBITDA of $59.4M.
In the most recent fiscal year, Cosmecca Korea achieved revenue of $381M and an EBITDA of $64.4M.
Cosmecca Korea expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Cosmecca Korea valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $396M | XXX | $381M | XXX | XXX | XXX |
| Gross Profit | $95.2M | XXX | $90.5M | XXX | XXX | XXX |
| Gross Margin | 24% | XXX | 24% | XXX | XXX | XXX |
| EBITDA | $59.4M | XXX | $64.4M | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 17% | XXX | XXX | XXX |
| EBIT | $46.5M | XXX | $43.9M | XXX | XXX | XXX |
| EBIT Margin | 12% | XXX | 12% | XXX | XXX | XXX |
| Net Profit | $32.9M | XXX | $31.1M | XXX | XXX | XXX |
| Net Margin | 8% | XXX | 8% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $43.8M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Cosmecca Korea's stock price is KRW 50300 (or $37).
Cosmecca Korea has current market cap of KRW 537B (or $391M), and EV of KRW 613B (or $446M).
See Cosmecca Korea trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $446M | $391M | XXX | XXX | XXX | XXX | $2.97 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Cosmecca Korea has market cap of $391M and EV of $446M.
Cosmecca Korea's trades at 1.2x EV/Revenue multiple, and 6.9x EV/EBITDA.
Equity research analysts estimate Cosmecca Korea's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cosmecca Korea has a P/E ratio of 11.9x.
See valuation multiples for Cosmecca Korea and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $391M | XXX | $391M | XXX | XXX | XXX |
| EV (current) | $446M | XXX | $446M | XXX | XXX | XXX |
| EV/Revenue | 1.1x | XXX | 1.2x | XXX | XXX | XXX |
| EV/EBITDA | 7.5x | XXX | 6.9x | XXX | XXX | XXX |
| EV/EBIT | 9.6x | XXX | 10.2x | XXX | XXX | XXX |
| EV/Gross Profit | 4.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | 11.9x | XXX | 12.6x | XXX | XXX | XXX |
| EV/FCF | 18.4x | XXX | 30.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCosmecca Korea's last 12 month revenue growth is 10%
Cosmecca Korea's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Cosmecca Korea's rule of 40 is 24% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Cosmecca Korea's rule of X is 40% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Cosmecca Korea and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Growth | 13% | XXX | 14% | XXX | XXX | XXX |
| Rule of 40 | 24% | XXX | 27% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 40% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 12% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Acme United | XXX | XXX | XXX | XXX | XXX | XXX |
| EZZ Life Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Live Verdure | XXX | XXX | XXX | XXX | XXX | XXX |
| Lavipharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Sarantis Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cosmecca Korea acquired XXX companies to date.
Last acquisition by Cosmecca Korea was XXXXXXXX, XXXXX XXXXX XXXXXX . Cosmecca Korea acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Cosmecca Korea founded? | Cosmecca Korea was founded in 1999. |
| Where is Cosmecca Korea headquartered? | Cosmecca Korea is headquartered in South Korea. |
| Who is the CEO of Cosmecca Korea? | Cosmecca Korea's CEO is Mr. Lim-Rae Jo. |
| Is Cosmecca Korea publicy listed? | Yes, Cosmecca Korea is a public company listed on KRX. |
| What is the stock symbol of Cosmecca Korea? | Cosmecca Korea trades under 241710 ticker. |
| When did Cosmecca Korea go public? | Cosmecca Korea went public in 2016. |
| Who are competitors of Cosmecca Korea? | Similar companies to Cosmecca Korea include e.g. Acme United, EZZ Life Science, Live Verdure, Lavipharm. |
| What is the current market cap of Cosmecca Korea? | Cosmecca Korea's current market cap is $391M |
| What is the current revenue of Cosmecca Korea? | Cosmecca Korea's last 12 months revenue is $396M. |
| What is the current revenue growth of Cosmecca Korea? | Cosmecca Korea revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Cosmecca Korea? | Current revenue multiple of Cosmecca Korea is 1.1x. |
| Is Cosmecca Korea profitable? | Yes, Cosmecca Korea is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Cosmecca Korea? | Cosmecca Korea's last 12 months EBITDA is $59.4M. |
| What is Cosmecca Korea's EBITDA margin? | Cosmecca Korea's last 12 months EBITDA margin is 15%. |
| What is the current EV/EBITDA multiple of Cosmecca Korea? | Current EBITDA multiple of Cosmecca Korea is 7.5x. |
| What is the current FCF of Cosmecca Korea? | Cosmecca Korea's last 12 months FCF is $24.2M. |
| What is Cosmecca Korea's FCF margin? | Cosmecca Korea's last 12 months FCF margin is 6%. |
| What is the current EV/FCF multiple of Cosmecca Korea? | Current FCF multiple of Cosmecca Korea is 18.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
